Experimental parathyroid hormone gene therapy using ØC31 integrase

Area of Science:

• Genetics
• Molecular Biology
• Gene Therapy

Background:

• Hypoparathyroidism treatment traditionally involves calcium and vitamin D, but parathyroid hormone (PTH) replacement is a more physiologic option.
• Current PTH synthesis is complex and expensive, creating a need for alternative therapeutic strategies.
• Gene therapy offers a potential solution to overcome the limitations of traditional PTH replacement.

Purpose of the Study:

• To investigate the efficacy of the ØC31 integrase system for site-specific genomic integration of the PTH gene.
• To assess the expression and secretion of PTH following gene integration in vitro and in vivo.
• To evaluate the potential of PTH gene therapy for hypoparathyroidism.

Main Methods:

• Cotransfection of 293 HEK cells with PTH-attB plasmid and ØC31 integrase plasmid.
• Assessment of PTH expression and secretion using immunoradiometric assays.
• Hydrodynamic injection of PTH-attB plasmid into mice, followed by plasma PTH measurement and genomic DNA analysis for site-specific integration.

Main Results:

• PTH was successfully expressed and secreted from both 293 HEK cells and mouse hepatocytes.
• Pseudo-site analysis confirmed site-specific integration of the PTH cDNA into the host genomes in both in vitro and in vivo models.
• The ØC31 integrase system demonstrated efficiency and site-specificity in integrating the PTH gene.

Conclusions:

• The ØC31 integrase system is a viable tool for achieving site-specific genomic integration of therapeutic genes like PTH.
• This technology shows significant potential for developing gene therapies, particularly for hypoparathyroidism.
• Future research should focus on regulating PTH expression and secretion for successful clinical translation.